Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo
- 1 July 1996
- Vol. 48 (1) , 164-170
- https://doi.org/10.1016/s0090-4295(96)00109-4
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Inhibition of prostate cancer growth by estramustine and etoposideCancer, 1995
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.Journal of Clinical Oncology, 1994
- Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology groupCancer, 1993
- Inhibition of Prostate Cancer Growth by Estramustineand Etoposide: Evidence For Interaction at the Nuclear MatrixJournal of Urology, 1993
- Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerCancer, 1993
- Nuclear‐Cytoskeletal interactions: Evidence for physical connections between the nucleus and cell periphery and their alteration by transformationJournal of Cellular Biochemistry, 1992
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.Journal of Clinical Oncology, 1985
- Taxol: an antimitotic agent with a new mechanism of actionPharmacology & Therapeutics, 1984
- Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factorCell, 1981
- Taxol stabilizes microtubules in mouse fibroblast cells.Proceedings of the National Academy of Sciences, 1980